Early diagnosis of medullary thyroid carcinoma: Is systematic calcitonin screening appropriate in patients with nodular thyroid disease?

Oncologist

Volumn 16, Issue 1, 2011, Pages 49-52

  Costante, Giuseppe ^a   Filetti, Sebastiano ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Calcitonin; Medullary thyroid carcinoma; Thyroid cancer; Thyroid nodules

Indexed keywords

CALCITONIN;

ARTICLE; ASPIRATION BIOPSY; CALCITONIN BLOOD LEVEL; CANCER MORTALITY; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GENE MUTATION; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE RET; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; THYROID NODULE;

CALCITONIN; CARCINOMA, MEDULLARY; EARLY DIAGNOSIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952612359     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0344     Document Type: Article

References (17)

1. Leboulleux S, Baudin E, Travagli JP et al. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
2. Chiefari E, Russo D, Giuffrida D et al. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 1998;21:358-364.
3. Lombardo F, Baudin E, Chiefari E et al. Familial medullary thyroid carcinoma: Clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 2002;87:1674-1680.
4. Costante G, Durante C, Francis Z et al. Determination of calcitonin levels in C-cell disease: Clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009;5:35-44.
5. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
6. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109-142.
7. American Thyroid Association Guidelines Task Force; Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
8. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
9. Gharib H, Papini E, Paschke R et al; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest 2010;33(suppl 5):1-50.
10. Costante G, Meringolo D, Durante C et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450-455.
11. Rink T, Truong PN, Schroth HJ et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009;19:327-332.
12. Scheuba C, Kaserer K, Moritz A et al. Sporadic hypercalcitoninemia: Clinical and therapeutic consequences. Endocr Relat Cancer 2009;16:243-253.
13. Borget I, De Pouvourville G, Schlumberger M. Calcitonin determination in patients with nodular thyroid disease [editorial]. J Clin Endocrinol Metab 2007;92:425-427.
14. Cheung K, Roman SA, Wang TS et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: A cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008;93:2173-2180.
15. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89:163-168.
16. Doyle P, Düren C, Nerlich K et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 2009;94:2970-2974.
17. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86: 5658-5671.